MarketPeel
Insider Trading Intelligence
Pricing
…
CM

Claire Mazumdar

RLAY
DIRECTOR · RELAY THERAPEUTICS, INC. · CIK 0002034671
FILING MIX · LIFETIME39%/61%
BUYS
20
SELLS
31
TOTAL VALUE
$4.44M
COMPANIES
2
ACTIVE SINCE
Jun 2025
HOLDINGS NOW
410,099
AVG SELL PX
$19.41
TRADE KIND
SHOWING 51 / 51
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 33 pending
Forward-return performance of every backtestable P/S trade by Claire Mazumdar, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+58.33%-2.59%-0.47%-2.13%+0.93%—
14d12+58.33%-0.22%-0.07%-0.15%+0.29%—
30d12+41.67%+4.34%+2.09%+4.26%+14.89%—
60d12+41.67%+6.72%+6.18%+0.72%-2.98%—
90d12(1 pending)+36.36%+4.82%+8.31%-5.55%-7.62%—
180d12(8 pending)+0.00%+17.41%+3.58%+14.69%+14.56%—
1y12(12 pending)——————
2y12(12 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
RLAY · 32,947 shares · as of Jun 9, 2026
0105,310210,621315,931421,2412026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2025
2025
2025
2026
2026
FLOW · 20 buys / 31 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RLAY
RELAY THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
32,947——32,947Jun 9, 2026Jun 10, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
15,000$3.79$56.8K377,152May 18, 2026May 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
12,022$19.96$240.0K365,130May 18, 2026May 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
15,000——146,107May 18, 2026May 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
2,978$20.35$60.6K362,152May 18, 2026May 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
15,000$23.61$354.1K362,152Apr 20, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
15,000$3.79$56.8K377,152Apr 20, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
15,000——161,107Apr 20, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
7,454$3.79$28.2K355,072Apr 16, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
8,226——56,684Apr 16, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
7,454——130,546Apr 16, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
7,080——558,432Apr 16, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
8,226$4.44$36.5K347,618Apr 16, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
7,080$5.45$38.6K362,152Apr 16, 2026Apr 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
1,596$3.79$6.0K340,988Mar 20, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
1,596——176,107Mar 20, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
1,596$18.95$30.2K339,392Mar 20, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
6,905——177,703Mar 19, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
6,905$18.78$129.7K339,392Mar 19, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
6,905$3.79$26.2K346,297Mar 19, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
6,499$18.84$122.4K339,392Mar 18, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
6,499$3.79$24.6K345,891Mar 18, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
6,499——184,608Mar 18, 2026Mar 20, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
36,766$3.79$139.3K376,158Mar 9, 2026Mar 11, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
36,766$19.17$704.7K339,392Mar 9, 2026Mar 11, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
36,766——191,107Mar 9, 2026Mar 11, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
3,817$18.75$71.6K339,392Mar 6, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
3,817$3.79$14.5K343,209Mar 6, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
3,817——227,873Mar 6, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
1,786$3.79$6.8K341,178Mar 5, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
1,786——231,690Mar 5, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
1,786$18.74$33.5K339,392Mar 5, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
2,631——233,476Mar 4, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
2,631$18.73$49.3K339,392Mar 4, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
2,631$3.79$10.0K342,023Mar 4, 2026Mar 6, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
450,000——450,000Feb 2, 2026Feb 4, 2026 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
29,500——565,512Dec 16, 2025Dec 18, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
29,500$5.45$160.9K339,392Dec 16, 2025Dec 18, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
41,163$3.79$156.0K351,055Nov 24, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
41,163——236,107Nov 24, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
41,163$18.86$776.4K309,892Nov 24, 2025Nov 25, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
24,103$3.79$91.3K333,995Oct 16, 2025Oct 20, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
24,103——277,270Oct 16, 2025Oct 20, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
24,103$18.83$453.8K309,892Oct 16, 2025Oct 20, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
13,289$3.79$50.4K323,181Oct 15, 2025Oct 15, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
13,289——301,373Oct 15, 2025Oct 15, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
13,289$18.84$250.4K309,892Oct 15, 2025Oct 15, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE
Chief Executive Officer
11,445——314,662Oct 13, 2025Oct 15, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
Chief Executive Officer
11,445$3.79$43.4K321,337Oct 13, 2025Oct 15, 2025 ↗View →
BCAX
BICARA THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
11,445$18.92$216.5K309,892Oct 13, 2025Oct 15, 2025 ↗View →
RLAY
RELAY THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
421,241——421,241Jun 9, 2025Jun 11, 2025 ↗View →
Other insiders · RLAY
Loading peer insiders…
About this filer
CIK 0002034671
ROLE
Director
PRIMARY
RLAY
COMPANIES
2
ACTIVE SINCE
Jun 2025
MARKETPEEL · /INSIDER/0002034671DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback